医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ResearchDx, the Leading Contract Diagnostics Organization, Sponsors the Asia BioPharma Convention 2014

2014年03月11日 AM08:25
このエントリーをはてなブックマークに追加


 

SINGAPORE

ResearchDx, LLC of Irvine, California, USA today announced its sponsorship and attendance at the Asia BioPharm 2014 Convention in Singapore as part of its focus on the important Asian biopharmaceutical and diagnostics markets.

ResearchDx will be presenting at the Asia BioPharma Convention 2014 Meeting in Singapore, held March 10th-13th. “We are proud to be involved as a sponsor of the BioPharma Asia Convention 2014 meeting. This meeting brings together the key diagnostics and biopharmaceutical companies in the region and is the ideal venue to highlight our services,” said Dr. Philip Cotter, Principal and Co-Founder of ResearchDx.

As a Contract Diagnostics Organization, ResearchDx is targeting two major areas for Asian clients. “We can provide a strategic partnership to Asian companies looking to develop companion diagnostics or in vitro diagnostic products for the local, US or European markets. We provide a full range of companion diagnostics and in vitro diagnostics services,” said Dr. Mathew Moore, Co-Founder and Principal at ResearchDx.

In addition, ResearchDx provides comprehensive services to assist International Clinical Laboratories obtain US CLIA certification, as well as various additional Clinical Laboratory accreditations such as ISO or College of American Pathologists (CAP). “International CLIA certification, and ISO or CAP accreditation provides our clients with a competitive edge. These licensures have enabled our clients to successfully compete for multi-national based clinical trial studies,” said Dr. Philip Cotter.

ResearchDx is the leading Contract Diagnostics Organization (CDO) for the biopharmaceutical and diagnostic industries. The company provides comprehensive, integrated, flexible services for the in vitro diagnostic development process. From initial assay conceptualization, discovery, optimization and validation in a CAP/CLIA laboratory environment, through a complete set of clinical research services and on to regulatory approval, ResearchDx offers the services and solutions to meet complex diagnostics development needs. ResearchDx’s primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting. Additional information is available at www.researchdx.com.

CONTACT

ResearchDx
Philip D. Cotter, PhD, FACMG, FFSc(RCPA)
866-225-9195
/ 510-332-0477
pcotter@researchdx.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表